At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 34 enrolled
Drug / intervention
LY3022855drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1 Study to Identify the Immunomodulatory Activity of LY3022855 (IMC-CS4) in Patients With Advanced, Refractory Breast or Prostate Cancer
In Brief
A Phase 1 clinical trial evaluating LY3022855 for Neoplasms and Neoplasm Metastasis. Completed, enrolled 34 participants across 2 sites.
Detailed Summary
The main purpose of this study is to learn more about how the investigational drug, LY3022855, affects the immune system in participants with advanced breast or prostate cancer that has not responded to other treatments. Treatment may last up to 6 cycles (cycle = 6 weeks).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasms, Neoplasm Metastasis
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartMay 2015
Primary CompletionNov 2017
TodayJul 2026
First PostedOct 16, 2014
Enrollment StartMay 1, 2015
Primary CompletionNov 3, 2017
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 11.7 years ago
Interventions
LY3022855drug
Administered IV